The first-in-class Preservation
& Protection Solutions (PPS),
engineered to protect organs from Ischemia-Reperfusion-Injury

Protect the graft when it matters most and build the foundation for lasting transplantation success
Perla® is CE-Marked

1.

Organs need more than storage, they need protection.

Today’s market is limited to Standard cold storage solutions keep organs cold and static but fail to protect them against ischemia‑reperfusion injury (IRI). IRI is unavoidable in kidney and liver transplantation and is a major driver of primary non‑function, delayed graft function, early allograft dysfunction, and acute and chronic rejection.

2.

A critical step in transplantation

Despite major advances in our understanding of IRI, cold storage solution have barely evolved in over 30 years, leaving organs inadequately protected. Choosing the right preservation solution is the first and most important step in transplantation. It protects the organ from IRI and strongly influences early graft performance and longterm outcomes. Today’s transplantation landscape, shaped by increasing complexity and challenges, demands more than just cold storage; it requires active biochemical protection.

3.

Protection when it matters most.

With this imperative in mind, ALS developed Perla®. It is the first Preservation & Protection Solution (PPS) engineered to actively optimize organ protection through graft washout and cooling, while protecting against IRI.

A breakthrough composition

Perla® combines three well‑established medicinal substances, trimetazidine, carvedilol, and tacrolimus. They specifically targets the key biological drivers of IRI, preserving cellular integrity and metabolic reserves at the moment the graft is most vulnerable. By protecting cells during preservation, they provide better functional recovery of the organ at the time of perfusion.

These ancillary substances are within a PEG and Sodiumrich extracellular solution. PEG prevents red blood cell aggregation and sodium avoids vasocontraction of the vessels, thereby supporting optimal microcirculation during the flushing and cooling.

Perla® enhances organ protection and functional recovery by combining effective washout with targeted IRI‑protective agents.

Beyond cold storage solutions

Perla®’s high performance has been demonstrated in kidney transplant models (in vivo) and in both nonsteatotic and steatotic livers. In these studies, Perla preserved cellular function, limited cell death, and enhanced graft function and survival.  Preclinical studies were conducted to further validate Perla®’s performance in protecting organs from IRI, contributing to obtain CE marking. This regulatory approval enable the launch of a randomized controlled trial (RCT) and an observational registry, for further clinical evidence.

By design, Perla® goes beyond just maintaining an organ’s condition. It protects the graft’s molecular defense systems to withstand the of reperfusion, laying the foundation for successful transplantation.

You wish to discover Perla® in detail ?

You are a healthcare professional and would like to know more.
We are at your disposal to meet you and explain our innovation in detail.